Carvana (CVNA) shares have plunged amid Mark Walter’s growing liquidity crisis after TWG Global’s USD 2bln stake in CVNA, however, newly obtained Delaware filings show essentially the entire stake is already pledged to Citigroup, reports Hunterbrook
Newsquawk Staff ·
- Hunterbrook is long CVNA.
What it means
The disclosure that a large outside stake is essentially fully pledged to a lender reframes the selloff from a valuation story into a collateral-math story, a distinction that has mattered in past episodes of leveraged holders coming under pressure. When a concentrated position is encumbered, the holder's ability to sell or borrow against it further is already exhausted, which historically shifts the risk toward forced deleveraging by the pledgee if margin triggers are breached, and toward overhang that clears only when the lender's position is resolved. The pattern in comparable situations has been that pledged-block stress tends to play out in a sequence: first the liquidity headlines on the holder, then the market hunts for the trigger levels, then any disclosure or absence of disclosure about whether the lender has begun to move collateral. Worth distinguishing here is the holder's distress from the company's own fundamentals; nothing in the headline asserts CVNA's operations have changed, and episodes of this kind have often seen the stock decouple from the underlying business while the collateral chain dominates. The follow-ons are any further filings, any statement from the holder or the lender, and whether the borrow and short-interest picture changes as the story develops. The sourcing outlet's disclosed long position is a conflict disclosure the market will price into the credibility of the framing, though the Delaware filings themselves are the verifiable core.
- Daily US Equity Opening News: SPCX explores access to 80K US cell sites; OpenAI nears USD 30bln funding at $1.25T valuation
- American Express (AXP) to cut 5% of jobs
- US BROKER MOVES: HESM upgraded at Raymond James; NCLH downgraded at JPM
- Oracle (ORCL) to invest USD 1bln in partner ecosystem over 4 years
- Bristol-Myers Squibb (BMY) says Iza-Bren reduced the risk of progression or death by 59% in Phase 3 breast cancer study; median PFS 8.2 months vs 4.0 months for chemotherapy; cORR 40.5% vs 20.2%; mDOR 6.9 vs 4.2 months
Related headlines
- American Express (AXP) Q3 2026 (USD): EPS 5.42 (exp. 4.50), Revenue 20.1bln (exp. 20.1bln)2 hours ago
- Booz Allen (BAH) Q2 2026 (USD): Adj. EPS 1.76 (exp. 1.48), Revenue 2.80bln (prev. 2.81bln)2 hours ago
- SLB (SLB) Q3 2026 (USD): adj. EPS 0.64 (exp. 0.62), Revenue 9.45bln (exp. 9.27bln)2 hours ago
- Citi (C) has been granted approval by China for its securities unit5 hours ago
- Tesla (TSLA) has decided not to proceed with plans to produce Cybertruck for Australia and New Zealand13 hours ago
- OpenAI trims valuation target to USD 1.25tln after previously pitching a higher price, according to FT15 hours ago
- Newmont (NEM) says production growth is expected to begin in 2027 following previously flagged 2026 trough, adds Q3 gold production was broadly flat sequentially as anticipated15 hours ago
- SpaceX (SPCX) in talks to access 80,000 cell sites for new network15 hours ago
- Google (GOOG) announces general availability of an Anthropic-managed deployment option for Claude models on Google Cloud16 hours ago
- OpenAI is raising up to USD 30bln in funding round at a USD 1.25tln valuation, led by UAE investors, according to CNBC, citing sources; OpenAI is negotiating a commercial deal that would secure more computing capacity from the UAE17 hours ago
- Gilead Sciences (GILD) entered into a definitive agreement to acquire an oral IL-23R inhibitor program, including lead asset HCXT-2001, from PepStar Therapeutics Limited; deal valued at USD 1.27bln in upfront cash17 hours ago
- Newmont (NEM) Q3 2026 (USD): Adj. EPS 2.20 (exp. 2.06), Revenue 6.36bln (exp. 6.30bln), Adj. EBITDA 3.95bln (exp. 3.73bln)17 hours ago
- Bloom Energy (BE) Q3 2026 (USD): Adj. EPS 0.94 (exp. 0.69), Revenue 1.24bln (exp. 1.06bln)17 hours ago
- Western Digital (WDC) Q1 2027 (USD): Adj. EPS 4.64 (exp. 4.08), Revenue 4.38bln (exp. 4.14bln)17 hours ago
- Merck & Co (MRK) and Moderna (MRNA) say safety profile of Intismeran plus Keytruda was generally consistent with previously reported studies of combination; significantly reduced the risk of recurrence or death by 42% compared to Keytruda alone19 hours ago